Tianfang Pharmaceutical, a unit of Tongyong Technology China Pharmaceuticals,
received an NMPA supplemental-approval notice for diclofenac sodium
enteric-coated tablets after passing generic quality and efficacy consistency
evaluation. Indications include inflammatory and degenerative rheumatic
diseases, non-articular soft-tissue rheumatic pain, acute mild-to-moderate pain
and acute gout attacks. The product is listed on China’s national reimbursement
list (Category A).
